Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results

Travere Therapeutics in the NEWS
Yesterday, Feb. 15, 2024,  Travere Therapeutics, Inc. (TVTX) reported its fourth quarter and full year 2023 financial results and provided a corporate update.

Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics said, “With ongoing growth in demand for FILSPARI in IgAN and the initiation of the pivotal Phase 3 program of pegtibatinase in classical . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.